mattjames28
![]()
Posts:1
My wife has breast cancer Er/pr+ her2-. They are suggesting taxol following Adriamycin and cytoxan. However I read a study by the CALGB showing that with the above cancer type taxol showed no increased benefit. Anyone heard of this?
Thanks,
Matt
Forums
Reply # - July 6, 2016, 09:36 AM
Hi Matt,
Hi Matt,
Welcome to GRACE. I took a look at that study (which can be found here for anyone interested in reading it), and I think the results were not as clearly negative as you've stated. There was an increase in disease free survival and "a noticeable reduction in the incidence of contralateral breast cancer" which was more pronounced for HER2- patients. The paclitaxel arm didn't show a statistically significant increase in overall survival, but the authors believe that more extended follow-up may show more of an increase in OS, as it has in other trials in the adjuvant setting.
JimC
Forum moderator